LifeTech Scientific Corporation Announces 2021 Annual Results.

SHENZHEN, China: LifeTech Scientific Corporation (LifeTech, 1302.HK), a leading company specialized in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, today announced 2021 annual results.

During the year ended 31 December 2021, the Group achieved a revenue of approximately RMB925.3 million, representing an increase of approximately RMB283.0 million or approximately 44.1%. Mainland China remained as our largest market, where sales generated from the Chinese market accounted for approximately 83.6% of our total revenue for the year ended 31 December 2021.

As for the performance of business segments, the turnover contributed by the structural heart diseases business for the year ended 31 December 2021 was approximately RMB 331.1million, representing an increase of approximately 60.4%, of which the sales of LAmbre LAA occluder increased by approximately 83.8% and the sales of the three CHD occluders: HeartR, Cera and CeraFlex increased by approximately 29.6%, 88.2% and 16.6% respectively.

The turnover contributed by the peripheral vascular disease business was approximately RMB548.5million, representing an increase of approximately 33.4%, of which the sales of stent grafts and vena cava filters increased by approximately 38.2% and 15.8% respectively.

The turnover contributed by the cardiac pacing and electrophysiology business was approximately RMB45.7million, representing a growth of approximately 85.8%.

Gross profit of the Group increased by approximately 45.7% to approximately RMB747.5 million for the year ended 31 December 2021. Gross profit margin increased by 0.9% to approximately 80.8% for the year ended 31 December 2021.Operating profit increased by approximately 24.3% to approximately RMB328.7 million for the year ended 31 December 2021.Net profit attributable to owners of the Company for the year ended 31 December 2021 was approximately RMB292.5 million as compared with RMB216.1 million for the year ended 31 December 2020.

Excluding certain non-recurring items, the Group's operating profit increased by approximately 55.5% to approximately RMB 360.3 million, while the net profit attributable to owners of the Company for the year was approximately RMB 324.0 million, representing an increase of 76.8%. Such non-recurring items include (i) the other gains and losses resulting from financial assets at fair value through profit and loss and (ii) the share-based payment expenses.

...